Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Sionna Therapeutics files its Annual Report describing a clinical-stage CF franchise focused on NBD1 stabilizers and complementary modulators. The company reports lead programs SION-719 (Phase 2a PreciSION CF add-on to Trikafta) and SION-451 (Phase 1 dual-combination evaluation), with topline Phase 1 safety and PK data announced in June 2025 and Phase 2a enrollment of ~16 participants ongoing.
The report details preclinical validation using a CFHBE translational model linking in vitro chloride transport to sweat chloride and FEV improvements, patent families and license agreements with Sanofi and AbbVie, key development milestones, and material risks including continued operating losses and financing needs.
Sionna Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 12:00 p.m. Eastern Time. Stockholders will elect four class II directors to serve until 2029 and ratify Deloitte & Touche LLP as independent auditor for 2026.
Stockholders of record at the close of business on April 21, 2026, when 45,142,330 common shares were outstanding and entitled to vote, may participate. The company is using the SEC “Notice and Access” process, providing proxy materials online and offering Internet, telephone, mail, and in‑meeting voting options.
Sionna Therapeutics director-affiliated entity sells SION shares under 10b5-1 plan
Entities associated with director Peter A. Thompson reported open-market sales of a total of 55,345 shares of Sionna Therapeutics common stock at prices around $44.5 per share over two days. The transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.
The shares are held of record by OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC potentially deemed to share voting and investment power. After these sales, OrbiMed’s reported indirect holdings stand at 2,964,774 shares of Sionna Therapeutics common stock, and all reporting parties expressly disclaim beneficial ownership beyond any pecuniary interest.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed-related entities sold 52,397 shares on April 17 at $44.68 per share and 2,948 shares on April 18 at $44.52 per share, under a pre-arranged Rule 10b5-1 trading plan. After these indirect transactions through OrbiMed Private Investments VIII, LP, the reporting entities continued to hold 2,964,774 shares of Sionna Therapeutics common stock.
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC filed an amended ownership report on Sionna Therapeutics, Inc. They report shared voting and dispositive power over 2,967,722 shares of common stock, representing 6.6% of Sionna’s 44,998,073 outstanding shares as stated in the company’s recent annual report.
The filing notes that this amendment reflects a decrease of more than 1% in beneficial ownership following recent sales by OrbiMed Private Investments VIII, L.P. The OrbiMed entities manage these holdings through their investment structures and retain discretion over voting and disposition of the shares.
Sionna Therapeutics, Inc. director Peter A. Thompson reported indirect open-market sales of a total of 510,583 shares of common stock in three transactions. The shares were sold at prices between $44.51 and $45.34 per share pursuant to a Rule 10b5-1 trading plan.
The securities are held of record by OrbiMed Private Investments VIII, LP, an investment fund advised by OrbiMed entities with which Thompson is affiliated. Following these transactions, 3,020,119 shares of common stock remain indirectly held, reflecting a continuing sizable position.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed entities sold a total of 510,583 shares over three days at prices between $44.51 and $45.34 per share under a pre-arranged Rule 10b5-1 trading plan, and continued to hold 3,020,119 shares indirectly after the latest transaction.
The shares are held of record by OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC potentially deemed beneficial owners through their control relationships, subject to customary pecuniary-interest and beneficial-ownership disclaimers.
Sionna Therapeutics, Inc. Chief Legal Officer Jennifer Fitzpatrick reported an option exercise and share sale. On March 5, 2026, she exercised a non-qualified stock option for 10,250 shares of common stock at $6.11 per share and immediately sold the same number of shares in an open-market transaction at a weighted average price of $33.8555 per share.
The sale was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. The shares were sold in multiple trades at prices ranging from $32.56 to $34.83. Following these transactions, she reported 50,935 option shares remaining from this grant and no directly held common shares from this transaction.
Sionna Therapeutics, Inc. registered up to $250,000,000 of common stock for sale under an at-the-market sales agreement with Leerink Partners dated March 2, 2026.
The shelf prospectus is an automatic Form S-3 registration that permits one or more offerings of common stock, preferred stock, debt securities, warrants and units; specific terms will be provided in prospectus supplements. The sales agreement permits ongoing sales from time to time after effectiveness and Leerink may earn up to 3.0% commission on gross sales.